Selective Inhibitors of Nuclear Export Block Pancreatic Cancer Cell Proliferation and Reduce Tumor Growth in Mice

被引:90
作者
Azmi, Asfar S. [1 ]
Aboukameel, Amro [2 ]
Bao, Bin [1 ]
Sarkar, Fazlul H. [1 ]
Philip, Philip A. [2 ]
Kauffman, Michael [3 ]
Shacham, Sharon [3 ]
Mohammad, Ramzi M. [2 ]
机构
[1] Wayne State Univ, Dept Pathol, Detroit, MI 48201 USA
[2] Karyopharm Therapeut, Natick, MA USA
[3] Karmanos Canc Inst, Dept Oncol, Detroit, MI USA
基金
美国国家卫生研究院;
关键词
Exportin; Translocation; Nucleus; Small Molecule Inhibitor; CRM1; PROSTATE APOPTOSIS; PROTEIN PAR-4; IN-VIVO; EXPRESSION; COMBINATION; TRANSPORT; RECEPTOR; THERAPY; TARGET; CRM1;
D O I
10.1053/j.gastro.2012.10.036
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
BACKGROUND & AIMS: Tumor-suppressor proteins are inactivated by many different mechanisms, including nuclear exclusion by chromosome region maintenance (CRM)-1. Increased tumor levels of CRM-1 have been correlated with poor prognosis of patients with pancreatic cancer, making it a therapeutic target. Selective inhibitors of nuclear export (SINEs) bind to CRM-1 to irreversibly inhibit its ability to export proteins; we investigated a new class of SINEs in pancreatic cancer cells. METHODS: We studied the effects of SINE analogs in a panel of pancreatic cancer cell lines and nontransformed human pancreatic ductal epithelial cells using proliferation, apoptosis, immunoblot, co-immunoprecipitation, small inhibitor RNA, and fluorescence microscopy analyses. The effects of the SINEs also were investigated in mice with subcutaneous and orthotopic tumors. RESULTS: SINEs (KPT-185, KPT-127, KPT-205, and KPT-227) inhibited proliferation and promoted apoptosis of pancreatic cancer cells, but did not affect human pancreatic ductal epithelial cells. The nuclei of cells incubated with KPT-185 accumulated tumor-suppressor proteins (p27, FOXO, p73, and prostate apoptosis response-4 [PAR-4]) and inhibited interactions between CRM-1 and these proteins. Mutations in the region of CRM-1 that bind to SINEs (Cys-528), or small inhibitor RNA knockdown of PAR-4, prevented the ability of KPT-185 to block proliferation and induce apoptosis of pancreatic cancer cells. Oral administration of KPT-330 to mice reduced growth of subcutaneous and orthotopic xenograft tumors without major toxicity. Analysis of tumor remnants showed that KPT-330 disrupted the interaction between CRM-1 and PAR-4, activated PAR-4 signaling, and reduced proliferation of tumor cells. CONCLUSIONS: We identified SINEs that inhibit CRM-1 and promote nuclear accumulation of tumor-suppressor proteins in pancreatic cancer cells. Oral administration of the drug to mice reduces growth of xenograft tumors.
引用
收藏
页码:447 / 456
页数:10
相关论文
共 28 条
  • [1] Downregulation of PAR-4, a pro-apoptotic gene, in pancreatic tumors harboring K-ras mutation
    Ahmed, Mansoor M.
    Sheldon, David
    Fruitwala, Mushtaq A.
    Venkatasubbarao, Kolaparthi
    Lee, Fun Y.
    Gupta, Seema
    Wood, Craig
    Mohiuddin, Mohammed
    Strodel, William E.
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2008, 122 (01) : 63 - 70
  • [2] MI-219-zinc combination: a new paradigm in MDM2 inhibitor-based therapy
    Azmi, A. S.
    Philip, P. A.
    Beck, F. W. J.
    Wang, Z.
    Banerjee, S.
    Wang, S.
    Yang, D.
    Sarkar, F. H.
    Mohammad, R. M.
    [J]. ONCOGENE, 2011, 30 (01) : 117 - 126
  • [3] PAR-4 as a possible new target for pancreatic cancer therapy
    Azmi, Asfar S.
    Philip, Philip A.
    Zafar, Syed F.
    Sarkar, Fazlul H.
    Mohammad, Ramzi M.
    [J]. EXPERT OPINION ON THERAPEUTIC TARGETS, 2010, 14 (06) : 611 - 620
  • [4] MDM2 inhibitor MI-319 in combination with cisplatin is an effective treatment for pancreatic cancer independent of p53 function
    Azmi, Asfar S.
    Aboukameel, Amro
    Banerjee, Sanjeev
    Wang, Zhiwei
    Mohammad, Momin
    Wu, Jack
    Wang, Shaomeng
    Yang, Dajun
    Philip, Philip A.
    Sarkar, Fazlul H.
    Mohammad, Ramzi M.
    [J]. EUROPEAN JOURNAL OF CANCER, 2010, 46 (06) : 1122 - 1131
  • [5] Chemoprevention of Pancreatic Cancer: Characterization of Par-4 and its Modulation by 3,3' Diindolylmethane (DIM)
    Azmi, Asfar Sohail
    Ahmad, Aamir
    Banerjee, Sanjeev
    Rangnekar, Vivek M.
    Mohammad, Ramzi M.
    Sarkar, Fazlul H.
    [J]. PHARMACEUTICAL RESEARCH, 2008, 25 (09) : 2117 - 2124
  • [6] Critical role of prostate apoptosis response-4 in determining the sensitivity of pancreatic cancer cells to small-molecule inhibitor-induced apoptosis
    Azmi, Asfar Sohail
    Wang, Zhiwei
    Burikhanov, Ravshan
    Rangnekar, Vivek M.
    Wang, Guoping
    Chen, Jianyong
    Wang, Shaomeng
    Sarkar, Fazlul H.
    Mohammad, Ramzi M.
    [J]. MOLECULAR CANCER THERAPEUTICS, 2008, 7 (09) : 2884 - 2893
  • [7] Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer
    Banerjee, S
    Zhang, YX
    Ali, S
    Bhuiyan, M
    Wang, ZW
    Chiao, PJ
    Philip, PA
    Abbruzzese, J
    Sarkar, FH
    [J]. CANCER RESEARCH, 2005, 65 (19) : 9064 - 9072
  • [8] RETRACTED: Notch-1 induces epithelial-mesenchymal transition consistent with cancer stem cell phenotype in pancreatic cancer cells (Retracted article. See vol. 423, pg. 153, 2018)
    Bao, Bin
    Wang, Zhiwei
    Ali, Shadan
    Kong, Dejuan
    Li, Yiwei
    Ahmad, Aamir
    Banerjee, Sanjeev
    Azmi, Asfar S.
    Miele, Lucio
    Sarkar, Fazlul H.
    [J]. CANCER LETTERS, 2011, 307 (01) : 26 - 36
  • [9] Chakraborty M, 2001, CANCER RES, V61, P7255
  • [10] Decreased expression of the pro-apoptotic protein Par-4 in renal cell carcinoma
    Cook, J
    Krishnan, S
    Ananth, S
    Sells, SF
    Shi, Y
    Walther, MM
    Linehan, WM
    Sukhatme, VP
    Weinstein, MH
    Rangnekar, VM
    [J]. ONCOGENE, 1999, 18 (05) : 1205 - 1208